SCHEMBL15051589

SCHEMBL15051589

CCc1ccccc1-c1nn(-c2cc(NC(C)=O)ncc2C)cc1-c1nc[nH]n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TYK2 P29597 3/20 0.32
JAK1 P23458 2/20 0.32
PIK3C3 Q8NEB9 1/20 0.32
ABL1 P00519 1/20 0.32
EGFR P00533 1/20 0.32
RIPK1 Q13546 1/20 0.32
MAP3K5 Q99683 1/20 0.32
NOTUM Q6P988 1/20 0.32
CRBN Q96SW2 1/20 0.31
MAPK1 P28482 1/20 0.31
HPGD P15428 1/20 0.31
HSD17B10 Q99714 1/20 0.31
DAPK1 P53355 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
ADORA3 P0DMS8 1/20 0.31
P2RY1 P47900 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15051877 0.91 ABL1 (0.36) NPC1RAB9ASMN1; SMN2TYK2JAK1
SCHEMBL15050840 0.89 ABL1 (0.36) SMN1; SMN2PIK3C3ABL1EGFRMAPK1
SCHEMBL15051573 0.88 ADORA3 (0.42) NPC1RAB9ASMN1; SMN2ABL1HPGD
SCHEMBL15051698 0.86 AR (0.35) NPC1RAB9ASMN1; SMN2TYK2PIK3C3
SCHEMBL15051323 0.86 PIK3CA (0.37) NPC1RAB9ASMN1; SMN2PIK3C3ABL1
SCHEMBL15051606 0.84 NPC1 (0.32) NPC1RAB9ASMN1; SMN2PIK3C3ABL1
SCHEMBL15051703 0.83 ADORA3 (0.35) NPC1RAB9ASMN1; SMN2PIK3C3ABL1
SCHEMBL15051313 0.82 ABL1 (0.40) NPC1RAB9ASMN1; SMN2PIK3C3ABL1
SCHEMBL15051295 0.81 RAB9A (0.35) NPC1RAB9ASMN1; SMN2PIK3C3ABL1
SCHEMBL15051168 0.81 ABL1 (0.34) NPC1RAB9ASMN1; SMN2TYK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013096630-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 WO disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165464-A1 HETEROARYLS AND USES THEREOF PIK3C2B, PI4KB, PIK3R4 NPC1 819/4885RAB9A 119/4885SMN1; SMN2 3783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.